ACXP
Acurx Pharmaceuticals LLC
NASDAQ: ACXP · HEALTHCARE · BIOTECHNOLOGY
$2.16
+0.00% today
Updated 2026-05-01
Market cap
$5.62M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-5.32
Dividend yield
—
52W range
$1 – $21
Volume
3.8M
Acurx Pharmaceuticals LLC (ACXP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.51M | $2.20M | $2.03M | $4.75M | $6.04M | $5.40M | $1.83B |
| SG&A | $2.42M | $2.40M | $10.78M | $7.34M | $8.53M | $8.70M | $6.26B |
| Operating income | $-5.93M | $-4.60M | $-12.88M | $-12.09M | $-14.58M | $-14.10M | $-8.09M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-5.93M | $-4.60M | $-12.81M | $-12.09M | $-14.58M | $-14.10M | $-8.09M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-5.93M | $-4.60M | $-12.88M | $-24.19M | $-29.16M | $-14.10M | — |
| Interest expense | $0.00 | $0.00 | $66503.00 | $1224.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-5.93M | $-4.60M | $-12.68M | $-12.09M | $-14.58M | $-14.10M | $-7.97M |
| Net income growth (YoY) | — | +22.4% | -175.7% | +4.6% | -20.5% | +3.3% | +43.5% |
| Profit margin | — | — | — | — | — | — | — |